Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label Study to Evaluate the Mutual Drug-Drug Interaction Potential Between Denifanstat and Resmetirom in Healthy Adult Participants

Next Previous
Trial Profile

A Phase 1, Open-Label Study to Evaluate the Mutual Drug-Drug Interaction Potential Between Denifanstat and Resmetirom in Healthy Adult Participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Denifanstat (Primary) ; Resmetirom (Primary)
  • Indications Acne vulgaris; Astrocytoma; Breast cancer; Glioblastoma; Liver cancer; Liver disorders; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Non-small cell lung cancer; Prostate cancer
  • Focus Pharmacokinetics
  • Sponsors Sagimet Biosciences

Most Recent Events

  • 27 May 2026 Results presented in a Sagimet Biosciences media release.
  • 27 May 2026 According to a Sagimet Biosciences media release, phase 1 clinical data from this trial will be presented in posters at the European Association for the Study of the Liver (EASL) Annual Congress 2026, being held in Barcelona, Spain on May 27-30, 2026. Sagimet's late-breaking Phase 1 poster on the denifanstat/resmetirom combination was selected as a Best of EASL 2026 presentation.
  • 23 Jan 2026 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top